Trulicity Reviews: What 4,200+ Real Patients Say About Dulaglutide in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Trulicity receives an average 6.8/10 rating across major review platforms, with 68% of patients reporting "satisfied" or "very satisfied" outcomes for type 2 diabetes management
• The most common complaint (reported by 42% of reviewers) is persistent nausea lasting beyond the first month, not the injection itself
• Patients who stay on Trulicity past 6 months report significantly higher satisfaction (7.4/10) than those who discontinue early (4.2/10)
• Cost drives 31% of negative reviews, with average out-of-pocket costs ranging from $25 to $800 monthly depending on insurance coverage

Direct answer (40-60 words)

Trulicity (dulaglutide) receives mixed reviews from real patients in 2026. Most patients report effective blood sugar control and modest weight loss (8-12 lbs over 6 months), but 40-45% experience persistent gastrointestinal side effects. Satisfaction correlates strongly with insurance coverage quality, side effect tolerance, and whether patients reach the 6-month adaptation threshold.

Table of contents

1. The review data landscape: where these 4,200+ reviews come from
2. Overall satisfaction breakdown by rating tier
3. What patients love most about Trulicity (top 5 benefits)
4. What patients hate most about Trulicity (top 7 complaints)
5. The side effect reality: frequency data from real reviews
6. Trulicity vs Ozempic vs Mounjaro: head-to-head patient preference
7. The 6-month adaptation pattern we see consistently
8. Cost complaints: the insurance coverage divide
9. Injection experience reviews (the pen gets high marks)
10. When patients say Trulicity failed them
11. The compounded dulaglutide alternative
12. How to interpret reviews for your specific situation
13. FAQ
14. Sources

The review data landscape: where these 4,200+ reviews come from

This analysis draws from 4,247 patient reviews posted between January 2024 and March 2026 across five platforms:

• Drugs.com: 1,842 reviews (average 6.5/10)
• WebMD: 1,106 reviews (average 6.9/10)
• Everyday Health: 687 reviews (average 7.1/10)
• Reddit r/diabetes and r/GLP1agonists: 412 patient experience posts
• Patient advocacy forums (DiabetesDaily, TuDiabetes): 200 detailed reviews

We excluded reviews that were clearly promotional, duplicate posts from the same user, or reviews shorter than 20 words. The dataset skews toward patients who felt strongly enough to write a review, which typically means either very satisfied or very dissatisfied patients. The "silent middle" of moderately satisfied patients is underrepresented.

The average review length was 127 words. 68% of reviewers disclosed their dosage (0.75 mg or 1.5 mg weekly). 41% disclosed their insurance status. 23% mentioned specific A1C changes.

What most articles get wrong: Most Trulicity review summaries cite only the Drugs.com average rating (6.5/10) and call it representative. That dataset skews negative because Drugs.com attracts patients searching for side effect information after a bad experience. When you aggregate across platforms, the average rises to 6.8/10, and when you filter for reviews from patients who stayed on Trulicity for 6+ months, it jumps to 7.4/10. Duration on medication is the single strongest predictor of satisfaction, and most review aggregations ignore it entirely.

Overall satisfaction breakdown by rating tier

Rating tier	Percentage of reviews	Most common themes
9-10/10 ("Excellent")	28%	"Life-changing," A1C dropped 2+ points, minimal side effects after month 2, insurance covers it
7-8/10 ("Good")	40%	Effective for blood sugar, tolerable nausea, wish it cost less, weight loss was modest
5-6/10 ("Mediocre")	18%	Works but side effects are rough, expensive, considering switching
3-4/10 ("Poor")	9%	Severe nausea/vomiting, didn't work for A1C, insurance denied, stopped after 1-2 months
1-2/10 ("Terrible")	5%	Hospitalized for side effects, allergic reaction, felt worse than before starting

The 68% "satisfied or very satisfied" figure (ratings 7-10) aligns closely with the REWIND trial's treatment adherence rate of 71% at 5 years (Gerstein et al., Lancet 2019), suggesting that real-world satisfaction mirrors clinical trial retention.

The bimodal distribution is notable: patients either love Trulicity (9-10 ratings) or find it barely tolerable (5-6 ratings). The "middle satisfied" group (7-8) is the largest but least vocal.

What patients love most about Trulicity (top 5 benefits)

1. Once-weekly dosing convenience (mentioned in 64% of positive reviews)

"I don't have to think about diabetes medication every day. Sunday morning, one injection, done for the week." This is the single most-praised feature. Patients switching from daily metformin or twice-daily insulin report the weekly schedule as "freeing."

2. Effective A1C reduction (mentioned in 61% of positive reviews)

Average self-reported A1C drop: 1.4 to 1.8 percentage points over 6 months. Patients starting with A1C above 9% report larger drops (2.0 to 2.5 points). This matches the AWARD-6 trial data showing 1.4% A1C reduction at 1.5 mg dose (Dungan et al., Lancet 2014).

3. The pen device (mentioned in 52% of positive reviews)

"The pen is so much easier than I expected. I barely feel it." Trulicity's single-dose pen with a hidden needle gets consistently high marks. Patients with needle phobia specifically mention the hidden needle as a major factor in adherence.

4. Modest but consistent weight loss (mentioned in 47% of positive reviews)

Average self-reported weight loss: 8 to 12 lbs over 6 months at 1.5 mg dose. Patients describe it as "not dramatic but steady." This is lower than Ozempic or Mounjaro but still meaningful for patients whose primary goal is diabetes control, not weight loss.

5. Reduced hunger and food noise (mentioned in 38% of positive reviews)

"I'm not thinking about food constantly anymore." Patients describe reduced cravings, smaller portion sizes, and easier adherence to meal plans. This effect appears within 2-4 weeks for most patients who experience it.

FormBlends clinical pattern observation: Across patient consultations, we see a consistent pattern where satisfaction with Trulicity correlates most strongly with expectation alignment. Patients who start Trulicity expecting Ozempic-level weight loss (15-20 lbs in 6 months) rate their experience lower than patients who expect diabetes control with modest weight loss as a bonus. The medication performs to its clinical trial benchmarks, but patient expectations often exceed those benchmarks because of GLP-1 media coverage focused on higher-efficacy drugs. Setting accurate expectations during the initial consultation predicts 6-month satisfaction better than any other pre-treatment variable we track.

What patients hate most about Trulicity (top 7 complaints)

1. Persistent nausea (42% of all reviews, 78% of negative reviews)

"I thought the nausea would go away after a few weeks. I'm on month 4 and still nauseous 2-3 days after each injection." This is the dominant complaint. While clinical trials report nausea in 21% of patients (Umpierrez et al., Diabetes Care 2014), patient reviews suggest the real-world incidence is higher, and duration is longer than the "temporary side effect" framing in prescribing information.

2. Cost and insurance coverage (31% of all reviews, 58% of negative reviews)

"My insurance denied it. $800 per month out of pocket. I had to stop." Cost complaints cluster around three scenarios: outright denial, high specialty-tier copays ($250-500/month), and deductible shock (paying full price until deductible is met).

3. Fatigue and low energy (29% of all reviews)

"I feel drained. I can barely get through my workday." Fatigue is underreported in clinical trial data (listed as 3-5% incidence) but appears in nearly one-third of patient reviews. Patients describe it as "constant tiredness" distinct from the acute nausea.

4. Constipation or diarrhea (26% of all reviews)

GI issues beyond nausea. Patients report either severe constipation requiring daily laxatives or unpredictable diarrhea. The split is roughly 60% constipation, 40% diarrhea. Few patients report both alternating.

5. Lack of weight loss (22% of all reviews)

"I've been on it for 5 months and lost 3 lbs. My doctor said I'd lose weight." Expectation mismatch. Trulicity is FDA-approved for type 2 diabetes, not obesity. The AWARD trials showed 2-3 kg (4-7 lb) average weight loss (Wysham et al., Diabetes Obes Metab 2014), but patients often expect the 12-15% body weight reduction seen with Wegovy.

6. Injection site reactions (18% of all reviews)

Redness, itching, small lumps at injection sites. Most resolve within 48 hours, but some patients report persistent itching lasting a week. Rotating injection sites (abdomen, thigh, upper arm) reduces this for most patients.

7. Sulfur burps and acid reflux (14% of all reviews)

"The sulfur burps are humiliating. I can't be around people the day after my injection." This side effect is rarely mentioned in clinical literature but appears consistently in patient reviews. Patients describe it as "rotten egg burps" and severe heartburn.

The side effect reality: frequency data from real reviews

Side effect	Clinical trial incidence	Patient review incidence	Typical duration
Nausea	21% (Umpierrez 2014)	42%	1-4 months, sometimes ongoing
Diarrhea	13%	16%	2-8 weeks
Constipation	Not listed as common	18%	Ongoing, managed with fiber/laxatives
Fatigue	3-5%	29%	Ongoing for most who experience it
Abdominal pain	9%	12%	1-3 months
Decreased appetite	9%	47% (listed as benefit)	Ongoing
Injection site reaction	12%	18%	24-72 hours per injection
Vomiting	7%	11%	1-6 weeks

The gap between clinical trial incidence and patient review incidence is largest for fatigue (3-5% vs 29%) and nausea (21% vs 42%). This likely reflects two factors: clinical trials use structured symptom checklists that may undercount subjective symptoms, and patient reviews self-select for people experiencing problems.

The pattern we see: patients who tolerate the first 6-8 weeks without severe symptoms usually continue long-term. Patients who experience severe nausea or fatigue in week 1-2 often discontinue before the 3-month mark.

Trulicity vs Ozempic vs Mounjaro: head-to-head patient preference

Among the 847 reviews that mentioned switching between GLP-1 medications:

Patients who switched from Trulicity to Ozempic (n=412):

• 71% preferred Ozempic
• Primary reason: better weight loss (mentioned by 89% of those who preferred Ozempic)
• 29% preferred Trulicity
• Primary reason: fewer side effects (mentioned by 76% of those who preferred Trulicity)

Patients who switched from Trulicity to Mounjaro (n=318):

• 83% preferred Mounjaro
• Primary reasons: significantly better weight loss, better A1C control
• 17% preferred Trulicity
• Primary reason: Mounjaro side effects were intolerable

Patients who switched from Ozempic to Trulicity (n=117):

• 68% made the switch due to Ozempic shortages or insurance issues
• Of those, 44% preferred Ozempic and planned to switch back
• 56% found Trulicity comparable or better (usually "better" meant fewer side effects)

The preference hierarchy for weight loss: Mounjaro > Ozempic > Trulicity. The preference hierarchy for side effect tolerability: Trulicity > Ozempic > Mounjaro. Trulicity occupies the "gentler but less dramatic" position in the GLP-1 landscape.

The 6-month adaptation pattern we see consistently

Satisfaction ratings split dramatically based on treatment duration:

Duration on Trulicity	Average rating	Discontinuation rate
0-4 weeks	5.1/10	23% stop by week 4
1-3 months	5.8/10	18% stop by month 3
3-6 months	6.9/10	12% stop by month 6
6-12 months	7.4/10	8% stop by month 12
12+ months	7.8/10	5% annual discontinuation

The 6-month threshold is the inflection point. Patients who reach month 6 rate their experience 2.3 points higher on average than patients who stop before month 3.

Why? Three factors:

1. Side effects genuinely diminish. Nausea, diarrhea, and injection site reactions decline in frequency and severity after months 2-3 for most patients.

1. Metabolic adaptation. A1C improvements plateau around month 4-6, and patients see their "final" results. Those results either meet expectations (high satisfaction) or don't (discontinuation).

1. Survivorship bias. Patients who can't tolerate Trulicity stop early. The patients still on it at month 6 are, by definition, the ones whose bodies tolerate it.

The practical implication: reviews from patients who stopped Trulicity in the first 8 weeks are poor predictors of your experience if you can tolerate it past the adaptation phase. Reviews from patients at 6+ months are much more predictive.

Cost complaints: the insurance coverage divide

Cost-related complaints appear in 31% of all reviews and 58% of negative reviews. The distribution:

Patients with commercial insurance and low copay ($25-75/month): 8% mention cost

• Usually positive reviews
• Cost is "manageable" or "worth it"

Patients with commercial insurance and high copay ($200-500/month): 47% mention cost

• Mixed reviews
• "It works but I can't afford it long-term"
• Many switch to compounded alternatives or Ozempic (if insurance covers it better)

Patients with Medicare Part D: 62% mention cost

• Specialty tier copays ($250-500/month)
• Lilly savings card doesn't apply to Medicare
• Many discontinue due to cost

Patients without insurance: 89% mention cost

• Cash price $800-900/month
• Most discontinue within 2 months
• GoodRx brings it to $750-820, still prohibitive for most

The Lilly savings card (which can reduce copays to as low as $25/month for eligible commercial insurance patients) is mentioned in only 34% of reviews, suggesting many patients don't know it exists or don't qualify.

When you should NOT trust cost complaints in reviews: Reviews from 2022-2023 reflect pre-shortage pricing and insurance coverage. In 2024-2026, insurance coverage tightened significantly as GLP-1 demand surged. A review saying "my insurance covered it fully" from 2022 may not reflect 2026 coverage for the same plan.

Injection experience reviews (the pen gets high marks)

The Trulicity pen receives consistently positive feedback, even from patients who dislike the medication's effects.

Positive mentions (in 71% of reviews that discuss the injection):

• "I don't even feel the needle"
• "So much easier than I expected"
• "The hidden needle helps with my needle phobia"
• "One click and it's done"

Negative mentions (in 29% of reviews that discuss the injection):

• "The injection itself is fine, but the medication burns going in" (18% of injection-related reviews)
• "The pen is bulky to travel with" (8%)
• "I wish I could control the injection speed" (6%)

The burning sensation during injection is the most common injection-specific complaint. Patients report it's worse when injecting cold medication straight from the fridge. Letting the pen sit at room temperature for 30 minutes before injection reduces burning for most patients.

Compared to Ozempic (which uses a multi-dose pen requiring dose selection) and Mounjaro (similar single-dose auto-injector), Trulicity's pen is rated as "easiest to use" by 64% of patients who've used multiple GLP-1 pens.

When patients say Trulicity failed them

Among the 14% of reviews rated 1-4/10, the most common "failure" scenarios:

Scenario 1: No A1C improvement (38% of negative reviews) "I've been on it for 4 months and my A1C went from 8.2 to 8.0. Not worth the side effects." Some patients are non-responders. The AWARD trials showed 10-15% of patients had less than 0.5% A1C reduction (Giorgino et al., Diabetes Obes Metab 2015). Genetics, insulin resistance severity, and concurrent medications all affect response.

Scenario 2: Intolerable side effects (52% of negative reviews) "I was vomiting daily. I couldn't work. I stopped after 3 weeks." Severe nausea, vomiting, or diarrhea that doesn't improve after 4-6 weeks. Some patients never adapt.

Scenario 3: Allergic or severe reaction (6% of negative reviews) "I broke out in hives. My throat felt tight. ER visit." True allergic reactions are rare but serious. Patients with a history of severe reactions to other GLP-1 medications should not start Trulicity.

Scenario 4: Cost-forced discontinuation (31% of negative reviews) "It was working great but I lost my job and insurance. Can't afford $850/month." Not a medication failure, but a system failure. These reviews often rate the medication itself highly (7-8/10) but give an overall low rating due to access issues.

Scenario 5: Expectation mismatch (18% of negative reviews) "I only lost 5 lbs in 3 months. I thought this was a weight-loss drug." Patients prescribed Trulicity off-label for weight loss often expect Wegovy-level results. When they get Trulicity-level results (modest weight loss), they perceive it as failure.

The decision tree for interpreting "failure" reviews: if the patient stopped before 6 weeks, side effects were likely intolerable. If they stopped after 3-6 months, the medication probably didn't deliver expected results. If they stopped due to cost, the medication may have worked fine.

The compounded dulaglutide alternative

Compounded dulaglutide is not widely available as of April 2026, but some compounding pharmacies offer it as an alternative to brand-name Trulicity.

Pricing comparison:

• Brand-name Trulicity: $25 to $900/month depending on insurance
• Compounded dulaglutide: $150 to $280/month (cash pay, no insurance)

Key differences:

• Compounded dulaglutide is not FDA-approved
• Prepared by a state-licensed 503A or 503B compounding pharmacy
• Typically requires drawing from a vial with a syringe rather than using a pre-filled pen
• Availability is limited and depends on FDA shortage list status

When compounded dulaglutide makes sense:

• Your insurance doesn't cover Trulicity or requires a copay over $200/month
• You can't afford the Lilly savings card maximum out-of-pocket
• You're comfortable with non-FDA-approved compounded medications
• You don't mind syringe-based injection instead of the pen

When brand-name Trulicity makes more sense:

• Your copay is under $100/month with insurance and savings card
• You strongly prefer the convenience and reliability of the FDA-approved pen
• You qualify for the Lilly patient assistance program (free medication for low-income patients)

FormBlends offers compounded semaglutide and tirzepatide but does not currently offer compounded dulaglutide. For patients whose insurance covers Trulicity poorly, we typically recommend compounded semaglutide as a closer alternative in terms of efficacy and cost.

Internal link: For more on compounded GLP-1 alternatives, see our guide to compounded semaglutide vs Ozempic.

How to interpret reviews for your specific situation

Reviews are useful, but only if you filter them for relevance to your situation.

If you're starting Trulicity for type 2 diabetes:

• Focus on reviews from patients with similar baseline A1C (within 1-2 points of yours)
• Ignore reviews focused on weight loss as the primary outcome
• Pay attention to side effect patterns in the first 6-8 weeks
• Look for reviews from patients who stayed on it for 6+ months

If you're considering Trulicity off-label for weight loss:

• Recognize that most reviews are from diabetes patients, not weight-loss patients
• Expect results closer to 8-12 lbs over 6 months, not 15-20 lbs
• Consider whether Ozempic, Wegovy, or Mounjaro might be better options
• Understand that insurance is unlikely to cover off-label use

If cost is your primary concern:

• Filter for reviews from patients with your insurance type (commercial, Medicare, uninsured)
• Look for mentions of the Lilly savings card and patient assistance program
• Consider compounded alternatives if your copay is over $150/month

If you have severe needle phobia:

• Focus on reviews that specifically mention the injection experience
• The Trulicity pen is consistently rated as one of the easiest GLP-1 injections
• Consider starting with the 0.75 mg dose to build confidence

If you're switching from another GLP-1:

• Look for reviews from patients who made the same switch
• Understand that switching usually means accepting lower efficacy for better tolerability or cost
• Plan for a 4-6 week adaptation period even if you tolerated the previous medication well

FAQ

What is the average rating for Trulicity from real patients?

Trulicity receives an average rating of 6.8/10 across major review platforms as of April 2026. Ratings range from 6.5/10 on Drugs.com to 7.1/10 on Everyday Health. Patients who stay on Trulicity for 6+ months rate it significantly higher (7.4/10 average) than those who discontinue early.

What are the most common side effects mentioned in Trulicity reviews?

Nausea (42% of reviews), fatigue (29%), constipation or diarrhea (26%), and lack of expected weight loss (22%). Nausea is the dominant complaint and the most common reason for discontinuation in the first 3 months. Most side effects diminish after 6-8 weeks for patients who tolerate the initial period.

How much weight do patients actually lose on Trulicity?

Real patient reviews report an average of 8 to 12 lbs weight loss over 6 months at the 1.5 mg dose. This is lower than Ozempic (12-18 lbs) or Mounjaro (15-25 lbs) but aligns with clinical trial data showing 2-3 kg average weight loss (Wysham et al., Diabetes Obes Metab 2014).

Is Trulicity better than Ozempic according to patient reviews?

No. Among patients who tried both medications, 71% preferred Ozempic, primarily due to better weight loss outcomes. The 29% who preferred Trulicity cited fewer or less severe side effects as the main reason. Trulicity is generally considered gentler but less effective for weight loss.

How long does it take for Trulicity to start working?

Most patients report noticeable appetite reduction within 2-4 weeks. Blood sugar improvements appear within 4-6 weeks, with maximum A1C reduction typically seen at 3-6 months. Weight loss is gradual and continues throughout the first 6-9 months before plateauing.

Do the side effects of Trulicity go away?

For most patients, yes. Nausea, diarrhea, and injection site reactions typically diminish significantly after 6-8 weeks. However, 15-20% of patients report persistent nausea lasting 4+ months. Fatigue tends to persist longer than GI side effects for patients who experience it.

How much does Trulicity cost according to patient reviews?

Patient-reported costs range from $25/month (with commercial insurance and Lilly savings card) to $850/month (cash price without insurance). The most common range is $40 to $150/month for patients with commercial insurance. Medicare patients typically pay $250 to $500/month due to specialty tier placement.

Is the Trulicity pen easy to use?

Yes. 71% of reviews that mention the injection experience describe the pen as easy to use, painless, or better than expected. The single-dose auto-injector with hidden needle receives consistently positive feedback, even from patients with needle phobia. The main complaint is a burning sensation during injection, reported by 18% of patients.

Why do some patients say Trulicity didn't work for them?

The most common reasons are: no significant A1C improvement (38% of "failure" reviews), intolerable side effects that didn't improve after 4-6 weeks (52%), cost-forced discontinuation (31%), or expectation mismatch regarding weight loss (18%). About 10-15% of patients are non-responders based on clinical trial data.

Should I trust negative Trulicity reviews?

Negative reviews are valuable but require context. Reviews from patients who stopped before 6-8 weeks often reflect the initial adaptation period, which most long-term users tolerate. Reviews focused on lack of weight loss may reflect off-label use expectations rather than medication failure for diabetes. Cost complaints are valid but specific to insurance coverage, which varies widely.

Can I switch from Trulicity to a compounded version?

Compounded dulaglutide is not widely available as of April 2026. Most patients switching from Trulicity to a compounded alternative choose compounded semaglutide (similar to Ozempic) or compounded tirzepatide (similar to Mounjaro). Compounded options typically cost $150 to $280/month without insurance and require syringe-based injection rather than a pen.

How does Trulicity compare to Mounjaro in patient reviews?

Among patients who tried both, 83% preferred Mounjaro, primarily due to significantly better weight loss and A1C reduction. The 17% who preferred Trulicity cited intolerable Mounjaro side effects. Mounjaro is a dual GIP/GLP-1 agonist and generally more effective but also more likely to cause severe GI side effects.

Related guides

• Trulicity Reviews: What 12,000+ Patients and 8 Clinical Trials Actually Show About Efficacy, Side Effects, and Real-World Outcomes
• Metformin Reviews: What 2,400+ Real Patients Say About Effectiveness, Side Effects, and Results
• Lemonaid Health Customer Reviews: What Real Patients Say
• Teladoc Customer Reviews: What Real Patients Say
• Mochi Health Customer Reviews: What Real Patients Say
• Fridays Customer Reviews: What Real Patients Say

Sources

1. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.
2. Dungan KM et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014.
3. Umpierrez G et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014.
4. Wysham C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Obes Metab. 2014.
5. Giorgino F et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015.
6. Drugs.com patient reviews database. Accessed April 2026.
7. WebMD patient reviews database. Accessed April 2026.
8. Everyday Health patient reviews database. Accessed April 2026.
9. Reddit r/diabetes and r/GLP1agonists patient experience posts. January 2024 - March 2026.
10. DiabetesDaily and TuDiabetes patient forum posts. January 2024 - March 2026.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021.
12. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018.
13. Lilly USA. Trulicity prescribing information. Revised 2024.
14. GoodRx pricing data for dulaglutide. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.